Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
Beam Therapeutics Inc (BEAM) PT Lowered to $60 at RBC Capital
November 7, 2022 10:51 AM ESTRBC Capital analyst Luca Issi lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $60.00 (from $76.00) while maintaining a Sector Perform rating.
The analyst comments "BEAM is prioritizing the lead HbF-boosting SCD program over the next-gen Makassar. We caught up... More
Beam Therapeutics Inc (BEAM) PT Lowered to $103 at Stifel
November 7, 2022 9:32 AM ESTStifel analyst Benjamin Burnett lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $103.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "We are reiterating our Buy rating on BEAM following 3Q22 updates. Main pushbacks from bears have been on (potentially... More



